{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidha7jcmil2dauxz34wege5t737uv3ruzo62tmxnsb6t5g5zexr4i",
    "uri": "at://did:plc:wwyqal4cnqhuwyacdj7rqq3n/app.bsky.feed.post/3mg3rxh53maw2"
  },
  "path": "/t/generalizability-vs-transportability-in-trials/28551?page=3#post_59",
  "publishedAt": "2026-03-02T13:52:38.000Z",
  "site": "https://discourse.datamethods.org",
  "textContent": "Not quite sure what you’re getting at? There’s a difference in the event rate _between arms of an RCT_. The fact that this difference will change from trial to trial, even if the trials are designed identically, makes the notion that there’s a universal “NNT” for a given therapy very problematic (?) Contrast these trial-based risk differences with the absolute reduction in risk that we might estimate for an _individual_ patient in our clinic if he were to be offered treatment in the post-trial setting. I’m just saying that these trial-level risk differences will not necessarily translate to the risk reduction that our _individual_ patient might expect (yet this is what the “NNT” is suggesting we should do…).",
  "title": "Generalizability vs. Transportability in Trials"
}